Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) CFO Jane Henderson sold 6,000 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $48.26, for a total transaction of $289,560.00. Following the completion of the sale, the chief financial officer now directly owns 200,871 shares of the company’s stock, valued at approximately $9,694,034.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Apogee Therapeutics Stock Performance
NASDAQ APGE traded up $0.54 on Friday, reaching $48.36. 384,313 shares of the stock traded hands, compared to its average volume of 526,857. Apogee Therapeutics, Inc. has a 12 month low of $14.19 and a 12 month high of $72.29. The company has a fifty day moving average price of $43.57 and a 200-day moving average price of $48.02. The company has a market cap of $2.83 billion and a price-to-earnings ratio of -9.21.
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.60). As a group, research analysts anticipate that Apogee Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Apogee Therapeutics
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $87.00 price target on shares of Apogee Therapeutics in a report on Monday, May 13th. Bank of America started coverage on Apogee Therapeutics in a research report on Friday, May 10th. They set a “buy” rating and a $80.00 target price for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics has a consensus rating of “Buy” and an average target price of $73.00.
View Our Latest Report on Apogee Therapeutics
About Apogee Therapeutics
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Featured Articles
- Five stocks we like better than Apogee Therapeutics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Why is the Ex-Dividend Date Significant to Investors?
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- Stock Market Sectors: What Are They and How Many Are There?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.